Sarepta Therapeutics
- Country
- ๐บ๐ธUnited States
- Ownership
- Private, Public
- Established
- 1980-01-01
- Employees
- 1.3K
- Market Cap
- $13.4B
- Website
- http://www.sarepta.com
- Introduction
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.
An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy
- First Posted Date
- 2018-05-22
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 171
- Registration Number
- NCT03532542
- Locations
- ๐ฎ๐น
Fondazione Policlinico Universitario A Gemelli, Milano, Italy
๐ง๐ชUZ Leuven, Leuven, Belgium
๐บ๐ธChildren's Hospital of Wisconsin, Corporate Center Suite 540, Milwaukee, Wisconsin, United States
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 (Vesleteplirsen) in Patients With Duchenne Muscular Dystrophy (DMD)
- First Posted Date
- 2017-12-18
- Last Posted Date
- 2022-07-06
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT03375255
- Locations
- ๐บ๐ธ
Neuromuscular Research Center, Sacramento, California, United States
๐บ๐ธRare Disease Research, LLC, Atlanta, Georgia, United States
๐บ๐ธAnn & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
A Gene Transfer Therapy Study to Evaluate the Safety of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Genetic: delandistrogene moxeparvovec
- First Posted Date
- 2017-12-15
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT03375164
- Locations
- ๐บ๐ธ
Nationwide Children's Hospital, Columbus, Ohio, United States
Study of Eteplirsen in Young Participants With Duchenne Muscular Dystrophy (DMD) Amenable to Exon 51 Skipping
- First Posted Date
- 2017-07-17
- Last Posted Date
- 2021-12-09
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT03218995
- Locations
- ๐ง๐ช
Universitair ziekenhuis Gent, Gent, Belgium
๐ซ๐ทArmand-Trousseau Hospital, Paris, France
๐ฎ๐นSite Fondazione Policlinico Universitario Agostino Gemelli, Roma, Italy
rAAVrh74.MHCK7.DYSF.DV for Treatment of Dysferlinopathies
- First Posted Date
- 2016-03-16
- Last Posted Date
- 2021-05-13
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT02710500
- Locations
- ๐บ๐ธ
Nationwide Children's Hosptial, Columbus, Ohio, United States
Dose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystrophy (DMD) Patients
- First Posted Date
- 2015-08-21
- Last Posted Date
- 2021-05-17
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT02530905
- Locations
- ๐บ๐ธ
Kennedy Krieger Institute, Baltimore, Maryland, United States
๐บ๐ธDavid Geffen School of Medicine at UCLA, Los Angeles, California, United States
๐บ๐ธAnn & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD)
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- First Posted Date
- 2015-07-16
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 228
- Registration Number
- NCT02500381
- Locations
- ๐บ๐ธ
University of Florida, Gainesville, Florida, United States
๐จ๐ฟUniversity Hospital Brno, Brno, Czechia
๐ซ๐ทReference Centre for Neuromuscular Diseases, Nantes, France
Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular Dystrophy
- First Posted Date
- 2015-04-17
- Last Posted Date
- 2021-01-25
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 33
- Registration Number
- NCT02420379
- Locations
- ๐บ๐ธ
University of Iowa Children's Hospital, Iowa City, Iowa, United States
๐บ๐ธRare Disease Research Center, Atlanta, Georgia, United States
๐บ๐ธChildren's Hospital of Atlanta, Atlanta, Georgia, United States
Phase I/II Study of SRP-4053 in DMD Patients
- First Posted Date
- 2014-12-08
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT02310906
- Locations
- ๐บ๐ธ
Boston Children's Hospital, Boston, Massachusetts, United States
๐ฎ๐นPoliclinico Universitario A Gemelli, Rome, Italy
๐ซ๐ทInstitute de Myologie, Paris, France
Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy
- First Posted Date
- 2014-11-10
- Last Posted Date
- 2020-03-30
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT02286947
- Locations
- ๐บ๐ธ
Massachusetts General Hospital, Boston, Massachusetts, United States
๐บ๐ธUniversity of Rochester Medical Center, Rochester, New York, United States
๐บ๐ธNationwide Children's Hospital, Columbus, Ohio, United States